Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries has informed that it enclosed the copies of the press releases titled ‘FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC)’.

The above information is a part of company’s filings submitted to BSE.